title: Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
authors: 1 Diabetology Unit, Niguarda Hospital, Milan, Italy. 2 Tissue Therapy Unit, Niguarda Hospital, Milan, Italy. 3 Surgical Department, Niguarda Hospital, Milan, Italy. 4 Interventional Radiology Unit, Niguarda Hospital, Milan, Italy. 5 Anesthesiology Unit, Niguarda Hospital, Milan, Italy. 6 Division of Nephrology, Dialysis and Renal Transplantation, Niguarda Hospital, Milan, Italy.
authors: Federico
authors: F
authors: Bertuzzi
authors: Mario
authors: M
authors: Marazzi
authors: Luciano G
authors: LG
authors: De Carlis
authors: Antonio G
authors: AG
authors: Rampoldi
authors: Matteo
authors: M
authors: Bonomo
authors: Barbara
authors: B
authors: Antonioli
authors: Marta C
authors: MC
authors: Tosca
authors: Marta
authors: M
authors: Galuzzi
authors: Andrea
authors: A
authors: De Gasperi
authors: Giacomo
authors: G
authors: Colussi
mesh_terms: D064591:Allografts; D002096:C-Peptide / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis / Q000601:surgery*; D000068338:Everolimus / Q000009:adverse effects / Q000627:therapeutic use*; D000077270:Exenatide; D006442:Glycated Hemoglobin / Q000378:metabolism; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D013997:Time Factors; D016896:Treatment Outcome; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002096:C-Peptide; D000068338:Everolimus; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D010455:Peptides; D014688:Venoms; C517652:hemoglobin A1c protein, human